HealthDatar Cancer Genetics Receives US FDA Clearance for CellDx-Tissue Genomic Assay
Datar Cancer Genetics announced US FDA clearance for CellDx-Tissue, a comprehensive genomic profiling assay analyzing DNA and RNA from solid tumor tissue. The assay covers 517 cancer-associated genes and detects key gene fusions, supporting personalized cancer treatment decisions. This clearance enhances DCG's global precision oncology offerings and validates its scientific and quality standards.
Pr Newswire Apac··Nashik


